The Zendal group has decided to strengthen its business line of pharmaceutical-quality probiotics with a capital injection for the “ambitious international expansion plan” of its Porriño-based subsidiary Bialactis. According to Borme, this amounts to 100,000 euros. Bialacts has 23 items for sale and two new lines in their final stage of development. It has signed or is about to sign distribution agreements in Spain, Portugal, United Kingdom, China and other European and Latin-American countries.